QCG
OLMA icon

Quadrant Capital Group’s Olema Pharmaceuticals OLMA Stock Holding History

Quadrant Capital Group’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57
Closed -$1K – 2634
2021
Q4 		$1K Buy
+57
New +$1.18K ﹤0.01% 2360

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Quadrant Capital Group's OLMA Position: Q1 2022 in Review

Quadrant Capital Group sold out of Olema Pharmaceuticals (OLMA) in Q1 2022, closing a stake of 57 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in OLMA in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 91 funds tracked by Wall St. Rank hold OLMA as of Q1 2022.

  • Quadrant Capital Group reported no remaining Olema Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 57 Olema Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Quadrant Capital Group's Olema Pharmaceuticals position peaked at $1K in Q4 2021.
  • 91 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.